Foresight Diagnostics Completes Series A Financing to Accelerate Development of its Industry-Leading Minimal Residual Disease (MRD) Technology

▤ Summary

Foresight Diagnostics closed a $12.5 million Series A round led by Civilization Ventures and Bluebird Ventures with participation from Pear Ventures. The company will use the capital to move PhasED-Seq into the commercial phase and launch its first CLIA-validated assay for MRD-driven clinical trials in B-cell lymphomas. Its liquid biopsy platform uses next-generation sequencing to detect circulating tumor DNA with very high sensitivity and can identify relapse earlier than standard imaging. Foresight is also evaluating strategic partnerships and already has studies underway with clinical collaborators and pharmaceutical companies.

$ Funding

▦ Linked Companies